Skip to content

A Clinical Evaluation of Cervical Lymphatic-Venous Anastomosis for Therapeutic Intervention in Alzheimer's Disease: Assessment of Safety and Efficacy

A Clinical Evaluation of Cervical Lymphatic-Venous Anastomosis for Therapeutic Intervention in Alzheimer's Disease: Assessment of Safety and Efficacy

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108826
Enrollment
Unknown
Registered
2025-09-05
Start date
2025-04-22
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Delayed Surgery Group:lymphatic-venous anastomosis Surgery( Undergo surgery within six months.)
Early Surgery Group:lymphatic-venous anastomosis Surgery( Undergo surgery within one week.)

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Ability to provide a written informed consent form signed by the participant or a legal representative (e.g., immediate family member); 2.Age between 50 and 90 years (inclusive); 3.Clinically diagnosed with Alzheimer's disease; 4.Availability of relatively complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Evidence of any non-Alzheimer’s disease (AD) condition that may affect cognitive function, including but not limited to: frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson’s disease, corticobasal syndrome, Creutzfeldt–Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration, Huntington’s disease, normal pressure hydrocephalus, epilepsy, delirium, or hypoxia; 2. History or current presence of clinically significant neurological disorders (e.g., traumatic brain injury, stroke, brain tumor, or previous brain surgery) that, in the opinion of the investigator, may impair cognitive function.

Design outcomes

Primary

MeasureTime frame
Cognitive, Psychological, and Behavioral Assessments: CDR score;PET Imaging of Amyloid-ß (Aß) Deposition;

Secondary

MeasureTime frame
Cerebrospinal Fluid (CSF) Biomarker Levels: Total tau (tTau) Phosphorylated tau at threonine 181 (pTau181) Amyloid-ß 40 (Aß40) Amyloid-ß 42 (Aß42);Cognitive, Psychological, and Behavioral Assessments: Activities of Daily Living (ADL) scale Mini-Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI);Regional Brain Volume on MRI;

Countries

China

Contacts

Public ContactChongjie Cheng

The First Affiliated Hospital of Chongqing Medical University

358187887@qq.com+86 153 3458 7556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026